Tune Therapeutics Presents Positive Phase 1b/2a Proof of Concept Data on TUNE-401: a First-in-Class Epigenetic Silencer for Patients with Hepatitis B at EASL 2026

Initial clinical data shows deep and durable antiviral activity, including direct silencing of cccDNA, offering a possible pathway to a finite cure for HBV patients May 30, 2026 08:00 AM EDT DURHAM, NC, and SEATTLE, WA (BUSINESS WIRE) – Tune Therapeutics, a leading epigenome editing company, presented new data today at the European Association for […]